PUBLISHER: Grand View Research | PRODUCT CODE: 1611179
PUBLISHER: Grand View Research | PRODUCT CODE: 1611179
The global transcatheter devices market size is expected to reach USD 19.62 billion by 2030, registering a CAGR of 10.55% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increase in adoption of minimal invasive procedures, high prevalence of chronic diseases, and growing preference for transcatheter replacement or repair procedures over open heart surgery are the key factors contributing to the market growth. The demand for transcatheter devices is growing owing to the fact that they are minimally invasive in nature and offer shorter hospital stays and fast recovery to patients. This is another major factor positively impacting the market growth. Also, key players are focusing on developing advanced heart valve replacement/ repair therapies, for instance, Abbott in 2019 received a FDA approval for its fourth-generation MitraClip device - MitraClip G4 that offers physicians in the U.S. with an extensive range of clip sizes, and facilitates real time assessment of procedure, thereby enabling doctors to efficiently treat mitral valve disease.
The growing technological advancement and constantly increasing volume of transcatheter devices in the pipeline for aortic valve replacement and repair, tricuspid valve repair, mitral valve replacement and repair, coupled with a growing geriatric population at high risk for open surgery are some of the factors boosting their demand. The growth is mainly driven by increasing prevalence of several cardiovascular disorders such as rheumatic heart disorders, cerebrovascular diseases, hypertensive heart diseases, and inflammatory heart diseases.
According to American Heart Association estimates in 2016, nearly 840,768 deaths were registered in the U.S. due to various cardiovascular diseases. The increasing patient pool for heart valve disorders and growing demand for heart valve replacement are other key factors expected to drive growth of transcatheter valves during the forecast period. However, high costs of transcatheter heart valve repair/replacement devices, a stringent regulatory framework for their approval, and the need for lifelong surveillance of these artificial valves are some of the barriers limiting market growth.